CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

Phase 2 Completed 4 enrolled Matinas BioPharma Nanotechnologies, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or intolerant to standard non intravenous therapies.

Timeline

Start: 2016-09-27
Primary completion: 2021-11-09
Completion: 2022-08-06

Outcome

Met primary endpoint

paper All CAMB-treated patients reached clinical efficacy by 2 weeks, three at 400 mg twice daily and one at 200 mg twice-daily dosing. PMID 35699443 ↗

release “This third patient, with long-standing azole resistant mucocutaneous candidiasis, met the primary endpoint of the Phase 2a study” matinasbiopharma.com ↗

Publications

Desai JV, Urban A, Swaim DZ, Colton B, Kibathi LW, Ferre EMN, Stratton P, Merideth MA, Hunsberger S, Matkovits T, Mannino R, Holland SM, Tramont E, Lionakis MS, Freeman AF. Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0030822. doi: 10.1128/aac.00308-22. Epub 2022 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amphotericin B	Unknown	200 mg	Oral
Subject	Amphotericin B	Unknown	400 mg	Oral
Subject	Amphotericin B	Unknown	800 mg	Oral